Anti‐CD20 monoclonals (MoAbs) are used in a variety of autoimmune disorders. The aim is to eliminate memory B cells sustaining the tissue damage and the production of pathogenic autoantibodies, while preserving naïve cells. The disappearance of memory B cells and the repopulation by naïve cells correlate with good clinical response, while the reappearance of memory B cells and plasmablasts correlates with relapse or resistance to therapy. Anti‐CD20 induce extremely low B cell levels, requiring high‐resolution techniques. The immune monitoring protocol developed by ISCCA is described and validated, to provide a standardized method for the clinical decision‐making process during anti‐CD20 therapies in autoimmune diseases.

中文翻译：

---

用于监测自身免疫性疾病中抗 CD20 疗法的 ISCCA 流程协议

抗 CD20 单克隆抗体 (MoAb) 用于多种自身免疫性疾病。目的是消除维持组织损伤和产生致病性自身抗体的记忆 B 细胞，同时保留幼稚细胞。记忆 B 细胞的消失和幼稚细胞的重新增殖与良好的临床反应相关，而记忆 B 细胞和浆母细胞的重新出现与复发或对治疗的抵抗相关。抗 CD20 诱导极低的 B 细胞水平，需要高分辨率技术。描述并验证了 ISCCA 开发的免疫监测方案，为自身免疫性疾病的抗 CD20 治疗期间的临床决策过程提供标准化方法。